-
1
-
-
0034048349
-
Anti-cytokine therapy for rheumatoid arthritis
-
Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-29.
-
(2000)
Annu Rev Med
, vol.51
, pp. 207-229
-
-
Maini, R.N.1
Taylor, P.C.2
-
2
-
-
0033524159
-
Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial
-
Maini RN, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999;354:1932-9.
-
(1999)
Lancet
, vol.354
, pp. 1932-1939
-
-
Maini, R.N.1
St Clair, E.W.2
Breedveld, F.3
-
3
-
-
43249101134
-
-
Charles P, Eliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF alpha therapy in rheumatoid arthritis. J Immunol 1999163:1521-8.
-
Charles P, Eliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF alpha therapy in rheumatoid arthritis. J Immunol 1999163:1521-8.
-
-
-
-
4
-
-
0142218539
-
Survival during treatment with tumor necrosis factor blocking agents in rheumatoid arthritis
-
II:ii-3
-
Flendrie M, Creemers MCW, Welsing PMJ, et al. Survival during treatment with tumor necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl II):ii-3.
-
(2003)
Ann Rheum Dis
, vol.62
, Issue.SUPPL.
-
-
Flendrie, M.1
Creemers, M.C.W.2
Welsing, P.M.J.3
-
5
-
-
0036720662
-
Etanercept, infliximab and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow-up programme, in southern Sweden
-
for the South Swedish Arthritis group
-
Geborek P, Crnkic M, Petersson IF, for the South Swedish Arthritis group. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow-up programme, in southern Sweden. Ann Rheum Dis 2002:61:793-8.
-
(2002)
Ann Rheum Dis
, vol.61
, pp. 793-798
-
-
Geborek, P.1
Crnkic, M.2
Petersson, I.F.3
-
6
-
-
19944433874
-
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
-
Feltelius N, Fored CM, Blomqvist P, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 246-252
-
-
Feltelius, N.1
Fored, C.M.2
Blomqvist, P.3
-
7
-
-
20444481876
-
Treatment continuation in patients receiving biological agents or conventional DMARD therapy
-
Zink A, Listing J, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 1274-1279
-
-
Zink, A.1
Listing, J.2
Kary, S.3
-
8
-
-
3442891154
-
Infliximab dose and clinical status: Results of 2 studies in 1642 patients with rheumatoid arthritis
-
Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-45.
-
(2004)
J Rheumatol
, vol.31
, pp. 1538-1545
-
-
Stern, R.1
Wolfe, F.2
-
9
-
-
33846090262
-
-
Duclos M, Gossec L, Ruyssen-Witrand A, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 20006;33:2433-9.
-
Duclos M, Gossec L, Ruyssen-Witrand A, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 20006;33:2433-9.
-
-
-
-
10
-
-
7044227564
-
Updated consensus statement on biological agents, specifically tumor necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist for the treatment of rheumatic diseases, 2004
-
II:ii2-12
-
Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumor necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004;63(Suppl II):ii2-12.
-
(2004)
Ann Rheum Dis
, vol.63
, Issue.SUPPL.
-
-
Furst, D.E.1
Breedveld, F.C.2
Kalden, J.R.3
-
11
-
-
20144367312
-
Safety of biologic therapies - an update
-
Keystone EC. Safety of biologic therapies - an update. J Rheumatol 2005;32(Suppl 74):8-12.
-
(2005)
J Rheumatol
, vol.32
, Issue.SUPPL. 74
, pp. 8-12
-
-
Keystone, E.C.1
-
12
-
-
33846657544
-
Infections during tumor necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 709 patients
-
Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumor necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology 2007;46:327-34.
-
(2007)
Rheumatology
, vol.46
, pp. 327-334
-
-
Salliot, C.1
Gossec, L.2
Ruyssen-Witrand, A.3
-
13
-
-
0344876553
-
Infection and anti-tumor necrosis factor-alpha therapy
-
Zandman-Goddard G. Infection and anti-tumor necrosis factor-alpha therapy. IMAJ 2003;5:814-16.
-
(2003)
IMAJ
, vol.5
, pp. 814-816
-
-
Zandman-Goddard, G.1
-
14
-
-
0344583756
-
Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor alpha
-
Tweezer-Zaks N, Shiloach E, Spivak A, Rapoport M, Novis B, Langevitz P. Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor alpha. IMAJ 2003;5:829-30.
-
(2003)
IMAJ
, vol.5
, pp. 829-830
-
-
Tweezer-Zaks, N.1
Shiloach, E.2
Spivak, A.3
Rapoport, M.4
Novis, B.5
Langevitz, P.6
-
15
-
-
2642539404
-
Anti-tumor necrosis factor therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer
-
Symmons DPM, Silman AJ. Anti-tumor necrosis factor therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer. Arthritis Rheum 50:1703-6.
-
Arthritis Rheum
, vol.50
, pp. 1703-1706
-
-
Symmons, D.P.M.1
Silman, A.J.2
-
16
-
-
27844511909
-
The risk of lymphoma development in autoimmune diseases: A meta-analysis
-
Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44.
-
(2005)
Arch Intern Med
, vol.165
, pp. 2337-2344
-
-
Zintzaras, E.1
Voulgarelis, M.2
Moutsopoulos, H.M.3
-
17
-
-
34948854326
-
B-cell lymphoproliferation in chronic inflammatory rheumatic diseases
-
Hansen A, Lipsky PE. Dorner T. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol 2007;3:561-9.
-
(2007)
Nat Clin Pract Rheumatol
, vol.3
, pp. 561-569
-
-
Hansen, A.1
Lipsky, P.E.2
Dorner, T.3
-
18
-
-
34248547187
-
The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19562 patients during 89710 person-years of observation
-
Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19562 patients during 89710 person-years of observation. Arthritis Rheum 2007;56:1433-9.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 1433-1439
-
-
Wolfe, F.1
Michaud, K.2
-
19
-
-
34147219117
-
Survival of TNF antagonists in spondyloarthritis is better thdn in rheumatoid arthritis. Data from the Spanish registry BIOBADASER
-
Carmona L, Gomez-Reino IJ. Survival of TNF antagonists in spondyloarthritis is better thdn in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8:R72.
-
(2006)
Arthritis Res Ther
, vol.8
-
-
Carmona, L.1
Gomez-Reino, I.J.2
|